medRxiv preprint doi: https://doi.org/10.1101/2024.07.31.24311315; this version posted August 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Uncertainty Quantification in Cost-effectiveness Analysis for Stochastic-based Infectious Disease Models: Insights from Surveillance on Lymphatic Filariasis

Mary Chriselda Antony Oliver^{a,h,*}, Matthew Graham^h, Ioanna Manolopoulou^{b,c}, Graham F. Medley^d, Lorenzo Pellis^e, Koen B Pouwels^f, Matthew Thorpe^g, T. Deirdre Hollingsworth^h

^a University of Cambridge, Department of Applied Mathematics and Theoretical Physics, Wilberforce Road, Cambridge, CB3 0BN, UK ^bUniversity College London, Department of Statistical Science, Gower Street, London, WC1E 6BT, UK

^cThe Alan Turing Institute, London, NW1 2DB, UK

 d London School of Hygiene and Tropical Medicine, Centre for Mathematical Modelling of Infectious Disease and Department of Global Health and

Development, Keppel Street, London, WC1E 7HT, UK

^eUniversity of Manchester, Department of Mathematics, Oxford Road, Manchester, M13 9PL, UK

^fUniversity of Oxford, Health Economics Research Centre, Nuffield Department of Population Health, Oxford, OX3 7LF, UK

^gUniversity of Warwick, Department of Statistics, Coventry, CV4 7AL, UK

^hUniversity of Oxford, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Oxford, OX3 7LF, UK

Abstract

Cost-effectiveness analyses (CEA) typically involve comparing effectiveness and costs of one or more interventions compared to standard of care, to determine which intervention should be optimally implemented to maximise population health within the constraints of the healthcare budget. Traditionally, cost-effectiveness evaluations are expressed using incremental cost-effectiveness ratios (ICERs), which are compared with a fixed willingness-to-pay (WTP) threshold. Due to the existing uncertainty in costs for interventions and the overall burden of disease, particularly with regard to diseases in populations that are difficult to study, it becomes important to consider uncertainty quantification whilst estimating ICERs.

To tackle the challenges of uncertainty quantification in CEA, we propose an alternative paradigm utilizing the Linear Wasserstein framework combined with Linear Discriminant Analysis (LDA) using a demonstrative example of lymphatic filariasis (LF). This approach uses geometric embeddings of the overall costs for treatment and surveillance, disability-adjusted lifeyears (DALYs) averted for morbidity by quantifying the burden of disease due to the years lived with disability, and probabilities of local elimination over a time-horizon of 20 years to evaluate the cost-effectiveness of lowering the stopping thresholds for post-surveillance determination of LF elimination as a public health problem. Our findings suggest that reducing the stopping threshold from <1% to <0.5% microfilaria (mf) prevalence for adults aged 20 years and above, under various treatment coverages and baseline prevalences, is cost-effective. When validated on 20% of test data, for 65% treatment coverage, a government expenditure of WTP ranging from \$500 to \$3,000 per 1% increase in local elimination probability justifies the switch to the lower threshold as cost-effective.

Stochastic model simulations often lead to parameter and structural uncertainty in CEA. Uncertainty may impact the decisions taken, and this study underscores the necessity of better uncertainty quantification techniques within CEA for making informed decisions.

13

26

Keywords: Lymphatic filariasis, mathematical modelling, stopping threshold, cost-effective analysis, optimal transport

1. Introduction

2

1.1. Health Economics Motivation

15 Global health systems face enormous challenges as a result 16 3 of the rising demand for healthcare services and the finite re-4 sources available to them. While other factors such as equity 18 5 may play a role, a common aim for governments is to max-19 6 imise overall population health within the constraints of the 20 available healthcare budget. Planning, managing, and assess-21 ing health systems heavily relies on economic factors. The best 22 9 use of limited resources is guided by health economic analy-23 10 ses, which provide cohesive techniques for evaluating the cost-24 11 effectiveness of health interventions. 12 25

The economic evaluation of health interventions is normally based on the outcome and cost of the interventions. Depending on the choice of how the outcome and intervention is evaluated, one of the main methodologies used is the cost-effectiveness analysis (CEA). This is an economic evaluation technique in which two or more health interventions are compared in terms of incremental costs and incremental effects compared to standard of care, with the cost-effectiveness expressed using the incremental cost-effectiveness ratio (ICER) which is a measure dividing the incremental costs by the incremental effects. Most countries that regularly use CEA to guide policy decisions around the implementation and reimbursement of interventions specify in their health-economic guidelines that costutility analyses should be used, where the denominator of the

^{*}Corresponding author: mca52@cam.ac.uk; postal address: DAMTP, Cen-27 ICER is expressed in quality-adjusted life-years (QALYs) or tre for Mathematical sector in the sector base of the

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

disability-adjusted life-years (DALYs). The latter is more fre- 85
quently used in low- and middle-income countries (LMICs). 86
Given the focus on LMICs in this paper, DALYs will be used 87

from here onwards. 31 The interpretation of the ICER depends on where it lies on 89 32 the cost-effectiveness plane (refer Figure 1 in [20]). If the new 90 33 intervention is more effective and saves money compared to 34 standard of care (South East quadrant), or the new intervention 35 is less effective and more costly compared to standard of care 36 (North West quadrant), the ICER is negative and interpretation 92 37 is simple. In the former case the new intervention should clearly 93 38 be adopted from a cost-effectiveness point of view, whereas in 94 39 the latter case the intervention is clearly worse and should not 95 40 be adopted. 41 To determine whether an intervention likely improves over- 97 42

all population health within the healthcare budget constraints, 98 43 the ICER can be compared with a cost-effectiveness threshold 99 44 in situations where the intervention is more costly and more100 45 effective (North East quadrant) or less costly and less effec-101 46 tive (South West quadrant). Assuming the decision-maker in-102 47 deed wants to maximise overall population health, symmetrical103 48 threshold should be applied for both quadrants, whereby inter-104 49 ventions that are more effective and more costly should remain105 50 below the threshold and interventions that are less effective and 106 51 less costly should remain above the threshold. 107 52

If a new intervention costs more per DALY avoided than the108 53 healthcare it displaces, health opportunity costs exceed health109 54 benefits, and implementing the new intervention would be ex-110 55 pected to lead to an overall reduction in population health mea-111 56 sured in DALYs. Theoretically, the cost-effectiveness threshold112 57 [12; 48; 35] should reflect the point at which this occurs. Thus, 113 58 given the available budget, interventions that are more costly114 59 and more effective with an ICER below the threshold are ex-115 60 pected to improve overall population health, while similar in-116 61 terventions with an ICER above the threshold are expected to¹¹⁷ 62 worsen overall population health. 118 63

Characterizing uncertainty is crucial in CEA, particularly₁₁₉ 64 when evaluating the need for additional evidence. Value of₁₂₀ 65 Information (VoI) analysis enhances CEA by quantifying the121 66 benefit of reducing uncertainty in decision-making. In health122 67 decision-analytic models, VoI assesses the potential benefit ob-123 68 taining additional data aimed at reducing uncertainty in key₁₂₄ 69 parameters influencing decision uncertainty. Two key uncer-125 70 tainties are model input values and model structure, whereby126 71 VoI analyses in the literature typically only focus on parameter₁₂₇ 72 uncertainty and completely ignore model structure uncertainty.128 73 These models are typically law-driven due to a lack of long-129 74 term data. To quantify input uncertainty, a probability distribu-130 75 tion for true input values is propagated through the model using131 76 Monte Carlo sampling, known as probabilistic sensitivity anal-132 77 ysis (PSA) [15; 43]. However, PSA only addresses input uncer-133 78 tainty, not structural uncertainty, which is harder to quantify and₁₃₄ 79 requires judgments about the model's real-life representation. 135 80 Despite its potential, VoI analysis [56] is constrained by₁₃₆ 81 structural uncertainties, which are rarely quantified in model-137 82 based analyses. Not quantifying structural uncertainty implies₁₃₈ 83 that the model is a perfect representation of real-world pro-139 84

cesses and relationships. While VoI analysis for structural uncertainty using model selection and model averaging has been explored previously [44; 6], methods in this area are still underdeveloped. Addressing these limitations is essential to fully leverage VoI analysis in making informed and effective health-care policy decisions.

1.2. Theoretical Background on Lymphatic Filariasis

Lymphatic filariasis (LF), a debilitating neglected tropical disease caused by parasitic worms transmitted through mosquitoes, affects about 882 million people across 44 countries [54]. In 2000, the World Health Organization (WHO) launched the Global Program to Eliminate Lymphatic Filariasis (GPELF), aiming to eradicate LF as a public health problem (EPHP) in 73 endemic nations by 2020 [53]. By 2021, 19 countries, including Bangladesh and Lao People's Democratic Republic, were validated as having achieved EPHP, with 11 others under surveillance after halting large-scale treatment [53; 54].

The primary intervention involves annual mass drug administration (MDA) for at least five years in affected areas, employing drug combinations such as diethylcarbamazine (DEC) + albendazole (DA) or albendazole + ivermectin (IA) [54]. Some areas also utilize a triple combination ivermectin + DEC + albendazole (IDA) [28; 24]. To assess MDA impact and determine if infection levels have dropped below stopping thresholds, WHO recommends epidemiological monitoring surveys and transmission assessment surveys (TAS). The TAS uses the samples of blood smears, typically surveying children aged 5 years and above for microfilariae (mf) prevalence [54]. Current MDA guidelines advise a minimum of 5 rounds of treatment before a pre-TAS is used to determine whether a first full TAS should be conducted, known as TAS-1. MDA can be stopped if TAS-1 is passed. Two subsequent surveys must also be passed before EPHP can be validated, TAS-2 and TAS-3, each within 2-3 years of the previous assessment.

However, focusing solely on children may underestimate mf prevalence, potentially missing ongoing transmission due to higher mf prevalence in adults. This paper proposes to improve the sensitivity of TAS to evaluate mf prevalence in adults, targeting <0.5% mf prevalence. This involves randomly sampling approximately 30 sites with 40-60 adults per site to replicate the characteristics of an evaluation unit (EU). Achieving and sustaining WHO goals necessitates effective surveillance, identifying new cases post-EPHP target attainment. Intensive surveillance thresholds (<2% antigenamia (Ag), <1% mf) may still be inadequate, especially in areas with Culex transmission vectors [3; 16]. Mathematical and biological theories [1] propose a transmission breakpoint influenced by local transmission conditions and biological factors, in helminth infections such as LF which depend on sexual reproduction of the parasites, where low worm burdens diminish onward transmission, potentially leading to disease extinction in deterministic scenarios. Studies, have suggested that the breakpoint might be substantially lower than 1% mf prevalence [19; 34]. Stochastic extinction can still occur above this breakpoint but with a lower probability [16]. If MDA are halted after reaching the breakpoint, the

medRxiv preprint doi: https://doi.org/10.1101/2024.07.31.24311315; this version posted August 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license

low-level remaining transmission will diminish gradually tak-195 140 ing a longer time for LF extinction. 141

In this work, we aim to provide the first detailed model sim-197 142 ulations of reducing the TAS stopping threshold in LF from₁₉₈ 143 <1% to <0.5% mf prevalence in a sample of adults aged 20199 144 years and above. This facilitates the understanding of the dif200 145 ferent trade-offs between additional rounds of MDA treatment201 146 and rebounds that apply to the design of surveillance strategies.202 147 In this context, modelling can help us to understand how ad-203 148 justing the threshold used in TAS impacts decisions about the204 149 stop of interventions and at what cost. For many settings, a205 150 reduction in the threshold increases the probability of elimina-206 151 tion, decreases the number of treatment rounds required, and207 152 reduces costs. Importantly, however, in certain circumstances 153 (e.g., when coverage is lower), lower thresholds can imply an 154 increase in the number of rounds of treatment required to reach²⁰⁹ 155 that threshold (with increased costs) but help mitigate chronic²¹⁰ 156 conditions (such as lymphoedema and hydrocele) and result in 157 longer sustained elimination with fewer future rebounds. 158

To investigate the issues outlined above, here we use mathe-²¹² 159 matical models of the transmission dynamics of LF as a case²¹³ 160 study to assess the potential implications of modifying the²¹⁴ 161 threshold for TAS. The paper addresses a key question: What²¹⁵ 162 are the potential trade-offs encountered in uncertainty quantifi-216 163 cation of cost-effectiveness analysis on lowering the stopping²¹⁷ 164 threshold for TAS in adults aged 20 years and above from an²¹⁸ 165 economic, epidemiological and mathematical perspective? In²¹⁹ 166 this paper, we restrict to lowering the stopping threshold from²²⁰ 167 <1% mf prevalence to <0.5% mf prevalence for a sample of221 168 adults motivated by the work in [3] and [16]. Importantly, we 169 focus on areas with Culex mosquitoes as the major transmission₂₂₂ 170 vector using IA drug combinations for potential comparisons. 171

1.3. Contributions 172

This study investigates the following three specific sub-225 173 questions outlined below which highlight the key contributions²²⁶ 174 227 of our work: 175 228

- 1. What is the interplay between the dynamics of infection on₂₂₉ 176 DALY burden and elimination? In Section 5 we show the230 177 monotonic behaviour of the DALY burden and probability 178
- of elimination for different stopping thresholds, baseline231 179 mf prevalences and MDA coverages. 180 232
- 2. What are the dynamics of the costs both pre and post-MDA₂₃₃ 181 surveillance when the stopping threshold is lowered? In₂₃₄ 182 Section 5 we explain the tradeoff illustrated in the ob-235 183 served non-monotonic behaviour of the costs for different₂₃₆ 184 stopping thresholds, baseline prevalences and MDA cov-237 185 erages. 186
- 3. If lower stopping thresholds are required for elimination 187 of transmission, then are we realistically able to measure 188 them using current tools? In order to circumvent issues238 189 related to the ICERs to address this question using the239 190 CEA framework in Section 2, we instead adopt a linear₂₄₀ 191 formulation of Expected Incremental Net-Monetary Bene-241 192 fit (EINMB) metric for fixed country-level WTP values as242 193 recommended by the several studies [38; 52] for DALY_{S243} 194

averted and approximate the range of WTP for probability of elimination (due to lack of data) in order to align with the goals of GPLEF. We also extend the analysis to quantify uncertainty with every additional sample size using Value of Information Analysis (VoI) with the help of Expected Value of Sample Size (EVSI) metric for the optimum WTP values per DALY averted and unit increase in the probability of elimination for different stopping thresholds and baseline prevalences. Finally, we propose an alternate paradigm, the Linear Wasserstein Framework in Section 3 that might help us resolve some of the proposed limitations, particularly around structural uncertainty of the CEA framework.

Addressing these questions will help to assess whether lower thresholds have the potential to assist programmes in achieving LF local elimination goals and how such decisions impact programme costs aligning with the GPELF objectives.

1.4. Outline of the paper

We begin in Section 2 by summarizing the theoretical framework for CEA. In addition, we prescribe an alternative paradigm that circumvents structural uncertainties of CEA using the Linear Wasserstein framework in Section 3. The numerical implementation is then described in Section 4 and tested in Section 5. Finally, we will discuss our findings and present our conclusions in Section 6. For the reader's convenience we have provided a list of key terminologies used in the manuscript in Table C.15 (see Appendix C for more details).

2. Summary on Cost Effective Analysis (CEA) Framework

In this section, we extend the classic net-benefit framework to include resource implications alongside aligning with GPLEF goals by incorporating elimination probabilities [2]. Additionally, we incorporate Value of Information (VoI) analysis which directly addresses the potential implications of current uncertainty, not only in terms of the likelihood of modifying the current decision in light of new and more definitive evidence, but also in terms of the opportunity cost of the incorrect decision.

2.1. Notation and Basic Concepts

Health economic decision making aims to determine the optimal intervention considering costs and health impacts of various clinical effectiveness. A key metric is the Incremental Cost-Effectiveness Ratio (ICER), defined as the ratio of the difference in costs (ΔC) to the difference in health impacts (ΔE) between two interventions:

$$ICER = \frac{\Delta C}{\Delta E},\tag{1}$$

Here, we use a cost-utility analysis, where health impacts (ΔE) are expressed in disability-adjusted life years ($\Delta DALYs$) averted by quantifying overall disease burden due to morbidity and mortality. In the current analyses, we only include effects on morbidity (e.g., lymphoedema, hydrocele) as we assumed the intervention has no impact on mortality. For our analysis,

223

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

285

i=

we will use both DALYs averted and the probability of elim-276
ination. A strategy is considered cost-effective if the ICER
does not exceed the health planner's WTP per DALY averted
(WTP_{DALY}),

ICER =
$$\frac{\Delta C}{\Delta DALYs} \le WTP_{DALY}.$$
 (2)²⁷

The net-benefit framework circumvents issues with ICERs by²⁷⁹
 not having to deal with extended dominance (when one inter-²⁸⁰
 vention is less cost-effective than a combination of two or more²⁸¹
 interventions) by transforming the ICER into a linear additive²⁸²
 form, known as the net-monetary benefit (NMB).

$$\Delta C \leq \text{WTP}_{\text{DALY}} \cdot \Delta \text{DALYs} =: \tag{3}_{287}^{286}$$
$$0 \leq \text{WTP}_{\text{DALY}} \cdot \Delta \text{DALYs} - \Delta C = \text{NMB}(\text{WTP}_{\text{DALY}}), \tag{3}_{287}^{287}$$

By using NMB, which relies on single monetary values rather 253 than ratios, the framework simplifies the evaluation of mul-254 tiple interventions, regardless of which quadrant of the cost-255 effectiveness plane the ICER lies in. Given a Monte Carlo sam-256 ple of N iterates of the costs and DALYs averted (denoted by²⁸⁸ 257 the parameter set θ), a strategy is preferred over the comparator²⁸⁹ 258 if the expected NMB exceeds zero: 290 259 291

$$0 \le \mathbb{E}_{\theta}(\text{NMB}(\theta_i, \text{WTP}_{\text{DALY}})), \tag{4}$$

where θ is the parameter vector and $i = \{1, 2, \dots, N\}$ is the iterations per parameter to denote the samples drawn from the joint₂₉₂ distribution $p(\theta)$. Extending this framework to multistrategy₂₉₃ decision analysis between *J* strategies, the preferred strategy is₂₉₄ the one that maximizes the $\mathbb{E}_{\theta}(\text{NMB}(\theta_i, \text{WTP}_{\text{DALY}}))$: 295

$$\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta} \left(\text{NMB} \left(j, \theta_i | \text{WTP}_{\text{DALY}} \right) \right).$$
(5)29
29

We also include benefits related to the probability of elimina-²⁹⁹ tion of LF, aligning with GPELF goals using WTP per unit in-

crease in probability of elimination (WTP_{Elimination}). The NMB
 is reformulated as:

$$NMB(\theta_i) = 100 \cdot WTP_{\text{Elimination}} \times \Delta \mathbb{I}_{\text{Elimination}}(\theta_i) + WTP_{\text{DALY}} \times \Delta \text{DALYs}(\theta_i) - \Delta C(\theta_i),$$
(6)

Here, $\Delta \mathbb{I}_{\text{Elimination}}(\theta_i)$ is 1 if only one strategy achieves elimina-³⁰² tion, and 0 otherwise such that $\Delta \mathbb{I}_{\text{Elimination}}(\theta_i) = \mathbb{I}_{\text{Elimination}}^{j}(\theta_i) - ^{303}$ $\mathbb{I}_{\text{Elimination}}^{\text{Comparator}}(\theta_i)$. Analogous to the traditional NMB, the strategy³⁰⁴ that ought to be implemented is indicated by, ³⁰⁵

$$\max_{i=\{1,2,\cdots,J\}} \mathbb{E}_{\theta} \Big(\text{NMB} \Big(j, \theta_i | \text{WTP}_{\text{DALY}}, \text{WTP}_{\text{Elimination}} \Big) \Big), \quad (7)$$

273 Simultaneously, the framework allows for a probabilis 274 tic interpretation of cost effectiveness by conditioning on
 275 WTP_{DALY}, WTP_{Elimination} as follows,

$$\mathbb{P}(j \text{ is CE}|\text{WTP}_{\text{DALY}}, \text{WTP}_{\text{Elimination}}) = \frac{1}{N} \sum_{i=1}^{N} \mathbb{M}(j, \theta_i), \quad (8)_{310}^{308}$$

where

$$\mathbb{M}(j,\theta_i) = \begin{cases} 1 & \arg\max_{j\in 1:J} \mathrm{NMB}(j,\theta_i|\mathrm{WTP}_{\mathrm{DALY}},\mathrm{WTP}_{\mathrm{Elimination}}) \\ 0 & \mathrm{Otherwise} \end{cases}$$
(9)

The framework therefore presents a measure of uncertainty that the strategy with the highest expected NMB is optimal over all other strategies, given by the proportion of samples where the strategy has the highest NMB of all strategies.

In general terms, the Expected Value of Perfect Information (EVPI) [8] is the difference between the expected value of a decision made with perfect information and the expected value of a decision made with current knowledge. It represents the maximum amount a decision-maker would be willing to pay for perfect information to avoid the potential losses associated with uncertainty. EVPI is defined as,

$$EVPI = \mathbb{E}_{\theta}(\max_{j=\{1,2,\cdots,J\}} NMB(j,\theta_i|WTP_{DALY}, WTP_{Elimination})) - \max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta}(NMB(j,\theta_i|WTP_{DALY}, WTP_{Elimination})).$$
(10)

Here, the vector of parameters can be split in two components $\theta = (\phi, \psi)$, where ϕ is the subvector of parameters of interest (i.e., those that could be investigated further) and ψ are the remaining "nuisance" parameters:

$$\max_{\{1,2,\cdots,J\}} \mathbb{E}_{\psi|\phi}(\text{NMB}(j,\theta_i|\text{WTP}_{\text{DALY}},\text{WTP}_{\text{Elimination}})).$$
(11)

which is the value of learning ϕ with no uncertainty. Of course, we will never be in the position to completely eliminate the uncertainty on ϕ , so we then average over its current probability distribution while also subtracting the value of the current optimal decision to calculate the Expected Value of Partial Perfect Information (EVPPI) [8; 43; 22]. The economic value of eliminating all uncertainty about ϕ (assuming risk neutrality) is equal to the EVPPI which is given by:

$$EVPPI = \mathbb{E}_{\phi}(\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\psi|\phi}(NMB(j,\theta_i|WTP_{DALY},WTP_{Elimination}))) - \max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta}(NMB(j,\theta_i|WTP_{DALY},WTP_{Elimination})).$$
(12)

Expected Value of Sample Information (EVSI) [23] measures the value of collecting additional data X to inform ϕ , assuming X directly updates ϕ and is independent of $\psi | \phi$. EVSI is bounded above by EVPPI. If data X were observed as x, it would update ϕ 's distribution $p(\phi|x)$, impacting the net benefit distribution for each treatment. EVSI is the average value over all possible data sets:

$$EVSI = \mathbb{E}_{X}(\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta|X}(NMB(j,\theta_{i}|WTP_{DALY},WTP_{Elimination})))$$
$$-\max_{j=\{1,2,\cdots,J\}} \mathbb{E}_{\theta}(NMB(j,\theta_{i}|WTP_{DALY},WTP_{Elimination})).$$
(13)

In this paper, to estimate EVSI computationally we follow the efficient nested Monte Carlo method based on "moment matching" by [23]. The method improves computational efficiency by reducing the nested Monte Carlo error, using the moment

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

374

375

matching technique to approximate the distribution of the pos-362 311 terior samples more accurately (see for more details, Algorithm₃₆₃ 312 1 in Appendix A). Although, several other approaches [29]₃₆₄ 313 such as the Importance Sampling (IS), Regression techniques,365 314 Gaussian approximation method and Integrated Nested Laplace366 315 Analysis (INLA) [22] exist, we rely on moment matching for its367 316 ability to estimate EVSI for multiple alternative sample sizes₃₆₈ 317 with a fixed additional computational cost. We also note that₃₆₉ 318

Integrated Nested Laplace Analysis (INLA) is highly efficient
 for performing Bayesian inference, especially in latent Gaus-³⁷⁰
 sian models by treating the PSA simulations as a 'spatial prob-³⁷¹
 lem' and projecting from higher to lower dimension to evaluate³⁷²
 EVPPI by dimensionality reduction.

³²⁴ 2.2. Fundamental Issues using EVSI as a metric

There are several challenges that arise when using the EVSI³⁷⁶ metric:

 Assumptions on Distributions: Implementing EVSI using
 the moment-matching method (see Algorithm 1 in Ap-₃₇₈ pendix A) involves approximating the distribution of the₃₇₉ sample information using moments (mean, variance, etc.).₃₈₀
 This can introduce errors, especially if the true distribution₃₈₁ of the sample information is not well-approximated by the₃₈₂ moments.

Dependence on Prior Information: The quality of EVSI estimates using moment matching depends heavily on the prior information available. Poor or inaccurate priors can³⁸³ lead to misleading EVSI estimates.

Implementation Challenges: Moment matching is accu-³⁸⁵
 rate and efficient when the health economic model has a³⁸⁶
 low computation time but becomes more unfeasible as the³⁸⁷
 model runtime increases and inaccurate when the sample³⁸⁸
 size is less than 10.

4. Requires Accurate EVPPI Estimation: Moment matching³⁹⁰ is more accurate for studies that will have significant im-³⁹¹ pact on the underlying uncertainty in the decision-analytic³⁹²

model, i.e., the EVPPI of ϕ needs to be high compared to

the value of reducing all model uncertainty (i.e., EVPI),
 ideally greater than 40% [23].

While moment matching can be a useful tool for approxi-395 mating EVSI, these limitations must be carefully considered 396 and addressed to ensure accurate and reliable health economic 397 decision-making. 398

353 3. Linear Wasserstein Framework

This section introduces an alternative metric to EVSI for de-400 354 termining the cost-effectiveness of intervention strategies using401 355 the Linear Wasserstein Framework (also called "Linear Opti-402 356 mal Transport" (LOT)) which was originally formulated in [55].403 357 Wasserstein-like distances are metrics on probability measures.404 358 They can be motivated from a geometric point-of-view as they405 359 pay a cost based on rearrangement of mass. This means the dis-406 360 tance is assigned (loosely speaking) based on translations. The407 361

main obstacle concerning Wasserstein distances is the computational cost and a lack of off-the-shelf data analysis tools. This is where the linearisation of optimal transport distances plays an important role. The linearisation defines a map $P : \mathcal{P}(X) \to \mathbb{R}^k$ (for some *k*) such that the Wasserstein distance in $\mathcal{P}(X)$ is approximately the Euclidean distance in \mathbb{R}^k . In the Euclidean space we can easily apply several standard data analysis tools such as dimensionality reduction, classification and modelling.

3.1. Notations

Let $X, Y \subseteq \mathbb{R}^d$ with $\mu \in \mathcal{P}(X)$ and $\nu \in \mathcal{P}(Y)$. Given $\mu \in \mathcal{P}(X)$ and a transport map $T : X \to Y$ we can define the pushforward of μ by T as follows.

Definition 1. Let $\mu \in \mathcal{P}(X)$ and $T : X \to Y$ be a measurable map, the pushforward of μ by T, denoted as $T_{\#\mu}$ is the measure ν defined by,

$$\nu(B) = \mu(T^{-1}(B)).$$
(14)

for all measurable set $B \subseteq Y$.

3.2. Optimal Transport Formulations

Let us consider $T : X \to Y$ to be a Borel measurable function such that $T_{\#\mu} = \nu$. The *Monge formulation* [11] would be to find the transport map *T*, given the probability measures μ, ν , minimising the objective function in $\mathbb{M}(\mu, \nu)$, where

$$\mathbb{M}(\mu,\nu) := \inf_{T:T_{\#}\mu=\nu} \int_{X} |x-T(x)|^p \mathrm{d}\mu(x).$$
(15)

We call any *T* which satisfies $T_{\#\mu} = v$ a transport map and the minimizer of the optimisation problem in Eq. (15) as the optimal transport map T^* . It is often difficult to handle this non-convex optimisation problem in Eq. (15) due to its non-linearity in *T*.

We define the set $\Pi(\mu, \nu)$ of couplings between measures μ and ν to be the set of probability measures on the product space $\mathcal{P}(X \times Y)$ whose first marginal is μ and the second marginal is ν . For any transport map $T: X \to Y$, there exists an associated transport plan π such that,

$$\pi = (\mathrm{Id} \times T)_{\#}\mu. \tag{16}$$

where Id denotes the identity map. We recall that if $P^X : X \times Y \to X$ and $P^Y : X \times Y \to Y$ are the canonical projections, then the marginals are $P^X_{\#}\pi = \mu$ and $P^Y_{\#}\pi = \nu$.

The *Kantorovich formulation* [11] would be to minimise the objective function $\mathbb{K}(\mu, \nu)$, given the probability measures μ , ν , where

$$\mathbb{K}(\mu,\nu) := \inf_{\pi \in \Pi(\mu,\nu)} \int_{X \times Y} |x - T(x)|^p \mathrm{d}\pi(x,y).$$
(17)

The minimizer of Eq. (17) is the optimal transport plan π^* . In this sense, the *Kantorovich formulation* in Eq. (17) can viewed as a relaxation of the *Monge formulation*. The difficulty in proving the existence of maps that satisfy the constraint $T_{\#}\mu = v$ leads to mass splitting during transportation, especially in cases involving discrete measures where such transport maps may not be feasible. This modified formulation in Eq. (17) now describes the amount of mass $\pi(x, y)$ that can be transported from *x* to different positions at *y*.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

438

441

455

456

457

458

459

460

461

462

463

464

408 3.3. Wasserstein Distances

We denote the space of probability measures on *X* that have that have finite p^{th} moment, as follows:

$$\mathcal{P}_p(X) := \Big\{ \mu \in \mathcal{P}(X) : \int_X |x|^p \mathrm{d}\mu(x) < +\infty \Big\}.$$

So, when *X* is bounded $\mathcal{P}_p(X) = \mathcal{P}(X)$. This allows us to to 442 define the *p* – Wasserstein distance [11], which is the minimum transportation cost between μ and ν , as

$$d_{W^{p}}(\mu, \nu) = \begin{cases} \inf_{\pi \in \Pi(\mu, \nu)} \left(\int_{X \times Y} |x - y|^{p} d\pi(x, y) \right)^{\frac{1}{p}} & \text{for } 1 \le p < \infty, \\ \inf_{\pi \in \Pi(\mu, \nu)} \pi - \operatorname{ess sup}_{(x, y)} |x - y| & \text{for } p = \infty. \end{cases}$$
(18)⁴⁴⁰

The d_{W^p} distances are advantageous for Lagrangian modeling⁴⁴⁷ 414 due to their simplicity, metric properties (like symmetry), exis-448 415 tence of geodesics, Riemannian structure and theoretical bene-449 416 fits like existence of optimal transport maps and plans. How-450 417 ever, they require the inputs to be probability measures, are451 418 computationally expensive, and there is a lack off-the-shelf data452 419 analysis tools. We therefore opt for the Linear *p*-Wasserstein⁴⁵³ 420 454 Framework. 421

422 3.4. Linear Wasserstein Framework



Figure 1: The Linear *p*-Wasserstein framework embeds measures in the tangent₄₆₅ space of a fixed reference σ . As a consequence, the Euclidean distance between₄₆₆ the non-negative measures μ and ν is an approximation for the 2-Wasserstein distance $d_{W^2}(\mu, \nu)$. This figure is computed using ParaView.

The Linear p-Wassertein framework introduced by Wang in⁴⁶⁹ 423 [55], illustrated in Figure 1, has several applications in biomedi-470 424 cal imaging, analysis of 2-D point cloud data [5; 36], telescopic 471 425 and facial expressions [32; 31]. The term "linear" refers to the 472 426 (Euclidean) vector space structure that one gains after approx-473 427 imation. The method linearizes the Wasserstein distance by474 428 computing the projection to tangent space at a fixed reference. 475 429 To discuss the Linear p-Wasserstein framework in the con-476 430 tinuous setting we consider a domain $X \in \mathbb{R}^d$ that is a bounded,⁴⁷⁷ 431 convex and closed subset of \mathbb{R}^d with a non-empty interior,⁴⁷⁸ 432 alongside the probability measures $\mu_i \in \mathcal{P}(X) \; \forall \; i \in \{1, 2, \cdots, N\}^{479}$ 433 and a fixed reference $\sigma \in \mathcal{P}(X)$. The optimal transport map T_i^{*480} 434 between σ and μ_i satisfies, 435

$$d_{W^{p}}(\mu_{i},\sigma) = \left(\int_{X} |x - T_{i}^{*}(x)|^{p} \mathrm{d}\sigma(x)\right)^{\frac{1}{p}}$$
(19)⁴⁸³₄₈₄

where $T_{i\#}^* \sigma = \mu_i$. This provides the basis to formally introduce the linear Wasserstein distance for two measures say μ_1 and μ_2 .

$$d_{LOT_{W^p}}(\mu_1,\mu_2,\sigma) = \left(\int_X |T_1^*(x) - T_2^*(x)|^p \mathrm{d}\sigma(x)\right)^{\frac{1}{p}}.$$
 (20)⁴⁸⁸₄₈₉

This enables us to compute the linear embeddings in the form of projections $P : \mathcal{P}(X) \to T_{\sigma}\mathcal{P}(X)$ which are the velocity maps from the manifold to the tangent space. This can be expressed as.

$$P(\mu_i) = T_i^* - \mathrm{Id},\tag{21}$$

Equivalently, relating the Linear Wasserstein distance $d_{LOT_{WP}}$ to *p*-Wasserstein distance d_{WP} in equation (19) we can rewrite as follows,

$$d_{W^p}(\mu_i, \sigma) = \|P(\mu_i) - P(\sigma)\|_{L^p(\sigma)} = d_{LOT_{W^p}}(\mu_i, \sigma, \sigma).$$
(22)

Remark 2. This implies that the maps $P(\mu_i)$ form the linear embeddings in the form of projections from the p-Wasserstein space to L^2 (Euclidean) space, thereby preserving the optimal transport distance between μ_i and σ . It is assumed that $d_{\text{LOT}_{W^p}}(\mu_1,\mu_2,\sigma) \approx d_{W^p}(\mu_1,\mu_2)$ and the approximation depends on the curvature of the Wasserstein space and in general the linear Wasserstein distance is not equivalent (in terms of metric equivalence) to the Wasserstein space. However, when there is some special structure, such as when the measures are all translations or shearings then one gets established bounds [10] like $cd_{\text{LOT}_{W^p}}(\mu_1,\mu_2,\sigma) \leq d_{W^p}(\mu_1,\mu_2) \leq Cd_{\text{LOT}_{W^p}}(\mu_1,\mu_2,\sigma)$ where c, C are some positive constants.

3.5. Advantages of using the Linear Wasserstein Framework

The linear optimal transport (LOT) framework offers an alternative approach to the calculation of the Expected Value of Sample Information (EVSI), addressing several limitations associated with the moment matching method as outlined below:

- Approximation Accuracy: Unlike moment matching, which approximates the distribution using moments, LOT can directly handle the full distribution of the data by using the probability measures. This leads to more accurate representations of the underlying distributions, reducing approximation errors. According to ISPOR's recommendations [39], uncertainty in parameter input values should be characterized using probability distributions. Additionally, any dependencies between parameters should be represented by a joint, correlated probability distribution. We have modeled these inputs as a point cloud (discrete set of points in space).
- Handling High Dimensions: The LOT framework provides linear projections that help reducing the dimensionality from the ambient to the tangent space after applying off-the-shelf data analysis tools.
- 3. Distributional Assumptions: LOT does not rely on the assumption that the distribution can be adequately described by expectation and variance. It considers the entire distribution suitable for handling non-linearities and interactions inherent in the data, thus accommodating higher-order moments more naturally by preserving salient properties of the data and accounting structural uncertainty.
- 4. Independence from Prior Information: The LOT approach minimizes this dependency by utilizing an empirical distribution derived from observed data. This empirical focus means that the approach is less susceptible to the biases introduced by incorrect prior assumptions.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

550

551

552

553

By directly addressing the distribution of sample informa-544
tion and leveraging efficient optimization techniques, the LOT⁵⁴⁵
framework provides a robust and scalable uncertainty quantifi-546
cation tool to calculate cost-effectiveness analysis. This circum-547
vents many of the limitations associated with moment match-548
ing, leading to more accurate and reliable decision-making. 549

496 **4. Methods**

We utilize the stochastic TRANSFIL model [25] with pa-554 497 rameters previously estimated [26; 45] to represent transmis-555 498 sion by Culicine mosquitoes (for more details on the param-556 499 eters refer Table C.14 in Appendix C). The model simulates₅₅₇ 500 the health impacts of lymphatic filariasis (LF) and incorporates 501 mass drug administration (MDA) effects, based on simulated 502 target coverage, systematic nonadherence, and drug efficacy 503 560 [18]. We excluded other interventions such as vector control⁵ 504 for this study. We modeled closed populations of 100,000-505 500,000 people, reflecting EU sizes in standard TAS surveys 506 per WHO guidelines [54]. The detection parameters were fitted⁵⁶³ 507 using Bayesian MCMC to data from Malindi, Kenya, Colombo, 508 Gampaha and Sri Lanka [26]. MDAs were simulated at 65% 509 and 80% coverage. Systematic non-adherence was included by 510 calculating individual treatment probabilities based on coverage 511 and between-round correlation, parameterized with data from 568 512 Leogane, Haiti, and Egypt [18]. 513

570 The model also simulates health impacts of lymphoedema, 514 571 hydrocele, and acute adenolymphangitis (ADL) using pub-515 lished methods. Morbidity due to lymphoedema and hydrocele⁵⁷² 516 was modeled with data from India [13]. The model assumes 517 morbidity occurs after accruing a certain cumulative worm bur-574 518 den. ADL incidence was estimated twice per year in $70\%^{575}$ 519 of hydrocele patients and four times annually in 95% of lym-520 phoedema patients [14]. Prevalence was converted using pub-⁵⁷⁷ 521 lished disability weights [21]. Side-effects of MDA were not⁵⁷⁸ 522 considered, despite reports of 13% feeling unwell post-MDA,⁵⁷⁹ 523 as these effects were deemed minor [59]. Mental illness was 524 also excluded due to lack of accurate data, despite its recog-525 nized burden in LF [49; 30]. 526

For WHO-prescribed starting and stopping decisions [54],⁵⁸³ 527 we considered TAS surveys from 30 sites per EU. Baseline 528 585 prevalences were sampled from a normal distribution with 529 means of 5-10%, 10-20%, or 20-30%. In each site, we sam-530 pled 40-60 adults aged 20 years to evaluate TAS. If mf-positive 587 531 adults were below the stopping threshold MDA was halted un-588 532 til the next survey; otherwise, it continued. We iterated this⁵⁸⁹ 533 algorithm 1,000 times and reported mean baseline prevalences.590 534 Cost simulations considered TAS surveys (\$12,494.75 [7]) and⁵⁹¹ 535 MDA rounds (\$7,640.92 [47]) over a 20-year horizon, with dis-592 536 counting included. We note that for MDA restarts, the costs of 593 537 the MDA and TAS are doubled. 538 594

For cost-effectiveness analysis, using the Expected Incremental Net Monetary Benefit (EINMB) metric, we used <1%596 mf prevalence in children (aged 5 years and above) as the comparator. We simulated transmission dynamics and morbidity598 associated with LF, including DALY burden for 30 sites and599 a TAS-like survey across those sites. We investigated different MDA coverages (65% and 80%) and different baseline LF prevalences. We evaluated WTP_{DALY} for DALYs averted, reflecting opportunity costs and adjusted for purchasing power parity [51] using \$500 (Ghana), \$2,500 (Congo) and \$5,000 (Southern Africa) based on the provided country-specific percentage of GDP per capita estimate that underlies the DALY-4 estimation method by multiplying the total per individual DALY value times a specific proportion of the GDP per capita [35] for LMIC and WTP_{Elimination} per unit increase in local elimination ranging from \$0-\$10,000 [2]. We evaluated different stopping thresholds for Culicine transmitters using a model-based transmission dynamics, health, and economic impacts. To address our key questions, we examined:

- 1. Probability of elimination [46], i.e., the probability of achieving local elimination within 20 years post-MDA if mf prevalence in a sample of <1,700 adults aged \geq 20 years was below the stopping threshold.
- Health impact evaluation through DALYs averted for morbidity by quantifying the overall disease burden due to lymphoedema, hydrocele and ADL by the years lived with disability. In this context, we assume that the years of life lost due to premature death is zero as death due to LF is rare.
- 3. Costs due to MDA rounds and TAS surveys.
- 4. Computing the cost-effectiveness of lowering the stopping threshold to <0.5% in adults with the help of the EINMB metric (see Section 2). We note that for this metric we use the fixed country-specific WTP_{DALY} and vary across an approximate range of WTP_{Elimination}.
- 5. Evaluating the uncertainty in parameters (total costs, DALYs averted and/or probability of elimination) using Value of Information (VoI) methodology, with EVSI metric (see Section 2) implemented using moment matching method (see Algorithm 1 in Appendix A).
- 6. Evaluating the uncertainty in parameters (total costs, DALYs averted and/or probability of elimination) using the Linear Wasserstein Framework in conjunction with LDA (see Section 3). The total costs due to MDA rounds and TAS surveys, along with DALYs averted and probability of elimination, are represented as probability measures on point cloud data (discrete set of data points in space). Let μ_i denote the empirical measure associated with the *i*-th point cloud, defined as: $\mu_i = \frac{1}{m_i} \sum_{i=1}^{m_i} \delta_{x_i^{(i)}}$ where $x_i \in \mathbb{R}^d$ and m_i denotes total data points in each μ_i . We sample the point clouds so that each point cloud has the same fixed number m = 1000 data points, i.e. $\mu_i = \frac{1}{m} \sum_{j=1}^m \delta_{x_i^{(j)}}$ (up to relabelling of the $x_i^{(i)} \in \mathbb{R}^d$) for $i = \{1, 2, \dots, N\}$ and $j = \{1, 2, \dots, m\}$. Following this, we compute the projections $P(\mu_i)$ as defined in Eq. (21) for each measure μ_i . Using these projections, firstly we apply PCA to obtain the eigenvectors that accounts for principle variations of the distributions. We then use these projected eigenvectors from PCA as feature vectors (denoted as $\{\mathbf{X}_i\}_{i=1}^L$) along with three classes of baseline prevalences (5-10%,10-20%,20-30%) as labels (denoted

medRxiv preprint doi: https://doi.org/10.1101/2024.07.31.24311315; this version posted August 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license



Figure 2: Simplified timeline plots for a single population of size 1000 for 10 simulations illustrating the model-predicted temporal trends in mf prevalence (solid red lines), DALY burden are computed as the morbidity prevalence of lymphoedema, hydrocele and acute adenolymphangitis (dashed blue lines) times the disability weights [21] and cumulative wormburden (dotted green lines) for 5-10% mf prevalence using (a) <0.5%, (b) <1%, (c) <2% and (d) <5% as the stopping threshold criteria for TAS with 80% MDA coverage for a sample of adults.



Figure 3: Epidemiological outcomes for different mf stopping threshold preva-625 lences for TAS with 5-10% baseline prevalence with 80% MDA coverage of₆₂₆ different age-groups of the eligible population post-surveillance. Here, we represent the mean outcomes by randomly sampling approximately 30 sites with⁶²⁷ 40-60 people strafied by age per site to replicate the characteristics of an eval-628 uation unit (EU, < 500,000 people). Note that costs and DALYs averted are₆₂₉ normalized to the same scale for improved visualization in the plots. 630

as $\{y_i\}_{i=1}^{L}$) where L is the size of training dataset used as⁶³² 600 inputs for LDA [58] to classify the <0.5% mf threshold633 601 for different baseline prevalences relative to the reference.634 602 We note that we train the LDA on 80% of the feature vec-635 603 tor and labels (iteratively) and make predictions on the re-636 604 maining 20% of the unseen feature vector and labels. In637 605 this study, we use the fixed WTP_{DALY} as outlined above⁶³⁸ 606 and estimate the range for WTP_{Elimination} (see Algorithm 2639 607 in Appendix A for more details) 640 608

5. Results 609

The impact of MDA on the interruption of LF transmission644 610 and reduction of the disease burden using DALYs is dependent645 611

on the threshold criteria defined for passing the TAS, as illustrated in the example of a setting with a baseline prevalence of 5-10% and 80% MDA coverage of a single population size of 1000 for 10 simulations (Figure 2).

In Figure 3 (circles) replicating the characteristics of an EU, we find that the probability for local elimination at 5-10% baseline prevalence with 80% MDA coverage and a threshold of <0.5% mf prevalence was 89.2% (≥5 years), 91.8% (≥20 years), and 90.72% (entire eligible population). For a threshold of <1% mf prevalence, it was 80.05%, 83.8%, and 81.76%, respectively. Lowering the threshold increases the probability for local elimination across different prevalences, coverages, and age-groups. These trends follow across different baseline prevalences, MDA coverages and treatment strategies (refer B.1, B.2, and B.3 in Appendix B).

Additionally in Figure 3 (triangles), a lower threshold results in fewer MDA rounds and surveys due to reduced probability of restarting after stopping, hence lower costs. However, for the lowest baseline prevalence, restarting MDA is unlikely for either threshold for children and adults, with slightly higher costs for the lower threshold due to extra rounds needed. For the entire eligible population, higher threshold costs are greater due to MDA restarts. In general, more restarts occur at higher baseline prevalences and lower MDA coverage for all thresholds due to the stochastic nature of the model dynamics accounting for higher transmission and increased treatment rounds to achieve elimination (refer Tables B.4, B.5 and B.6, in Appendix B).

Figure 3 (squares) shows mean DALYs averted across different thresholds for 80% MDA coverage. Lowering the threshold results in more DALYs averted due to a reduction in worm burdens. Trends are similar for 65% MDA coverage. The choice of threshold depends on epidemiological context and economic considerations, including WTP_{DALY}.

To evaluate costs, health impact, and monetization benefits

641

642

643

medRxiv preprint doi: https://doi.org/10.1101/2024.07.31.24311315; this version posted August 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





Figure 4: a. EINMB based on the WTP for range of DALY averted for morbidity: \$500 (green), \$2500 (red), \$5000 (blue) for 5-10% (circles), 10-20% (triangles) and 20-30% (squares) baseline prevalence for a sample of adults. b. EINMB based on the WTP for 1% increase in probability of elimination from \$0-\$10,000 and the WTP_{DALY}: \$500 (green), \$2500 (red), \$5000 (blue) for sample of adults for (i) 5-10% - circles (ii) 10-20% - triangles (iii) 20-30% - squares baseline prevalences comparing <0.5% threshold in a sample of adults with respect to <1% threshold of mf prevalence in children (comparator).

of local elimination, we use expected incremental net mone-676 646 tary benefit (EINMB). Higher EINMB indicates optimal cost-677 647 effectiveness at a given WTP_{DALY}. Our findings (Figure 4a)678 648 show that at 80% coverage, switching to a lower threshold₆₇₉ 649 is cost-effective across all baseline prevalences, keeping costs680 650 per DALY averted below national WTP thresholds (positive681 651 EINMB). Variability in results is due to demographic factors682 652 such as age, treatment strategy, and population growth [40]. At₆₈₃ 653 65% coverage (Figure 4b), more rounds and surveys suggest684 654 switching to a lower threshold is cost-effective based on WTP685 655 per 1% increase in local elimination probability, aligning with686 656 GPELF goals (refer Tables B.7, B.8 in Appendix B). For WTPs687 657 of approximately \$4200, \$3000, and \$1000 per 1% increase in688 658 local elimination for different baseline prevalence, switching is689 659 recommended (Figure 4b, black solid line). 690 660

Health economic decision-analytic models are used to esti-691 661 mate the expected net benefits of competing decision options.692 662 The true values of the input parameters of such models are693 663 rarely known with certainty, and it is often useful to quantify⁶⁹⁴ 664 the value to the decision maker of reducing uncertainty through695 665 collecting new data. In the context of understanding how to696 666 measure the prevalence for different stopping threshold with697 667 precision, we need a handle to quantify uncertainty revolving698 668 around the costs due to MDA rounds and surveys alongside699 669 DALYs averted and unit increase in probability of elimination.700 670 In this light, the value of the proposed research design for ev-701 671 ery additional sample size can be quantified by the EVSI metric⁷⁰² 672 as defined in Section 2. In Figure 5 (a)-(b), we find that the⁷⁰³ 673 EVSI peaks around a WTP_{Elimination} of \$2,500-\$3,000 (max) for⁷⁰⁴ 674 <0.5% and <1% stopping threshold. On the other hand, for Fig-⁷⁰⁵ 675

of about \$1,500-\$1,700 (max) for <2% and < 5%. This corresponds to the fact that additional information obtained from extra EVSI per person (illustrated in Figure 5 by higher peaks in 0.5% than 5%) in lower stopping thresholds is more beneficial to account for uncertainty quantification of MDA stopping decisions as justified for 5-10% baseline prevalence. Additionally, in Tables B.11, B.12 and B.13 (see Appendix B), we find that moment matching is much faster than the benchmark nested Monte-Carlo method, although both converge to the same EVSI at larger sample sizes. Figure 5 illustrates the theoretically established trend in the fact that the EVSI (dark blue lines) approached the EVPPI (thick dark blue line below EVPI) as defined in Section 2 at larger sample sizes, indicating that the value of information gained from larger studies may approach the theoretical maximum value of removing the uncertainty of reaching elimination based on the different thresholds. In order to further test the robustness of the MDA stopping decision based on the cost-effectiveness of lower stopping threshold (< 0.5% mf prevalence in adults), we rely on the Linear Wasserstein Framework in conjunction with PCA and LDA. In Figure 6a, we find the scattergram of the costs with DALYs averted with 80% MDA coverage for different baseline prevalences (represented as circles, triangles and squares) show that the lower stopping thresholds (< 0.5%) are cost-effective using the fixed country-specific WTP_{DALY} ranging from \$500-\$5,000 when predicted on the unseen 20% of the feature vector (test sample). Each symbol represents the mean incremental costs to incremental DALYs averted to obtain a standardized comparison to the EINMB metric in Figure 4a. Likewise, in Figure

ure 5 (c)-(d) we see that the EVSI peaks around a WTP_{Elimination}





Figure 5: EVSI implemented using the moment matching method for different thresholds (a: <0.5%, b: <1%, c: <2% and d: <5%) to evaluate the uncertainty related to the cost-effectiveness of different stopping threshold for TAS under a range of WTP per unit increase in elimination for 5-10% baseline prevalence in a sample of adults with 65% MDA coverage.



Figure 6: Summary figure illustrating the variations in the cost-effectiveness of the lower threshold for TAS using the Linear Wasserstein framework by considering the total costs and DALYs averted, probability for elimination as inputs. The LOT embeddings are projected into a lower-dimension space using PCA and this reduced feature vector from PCA is trained using LDA (80:20 split) for classifying <0.5% threshold at different baseline prevalence (labels) depicted as (circles) 5-10%, (triangles) 10-20% and (squares) 20-30% alongside the WTP for DALY averted for morbidity: \$500 (green), \$2,500 (red), \$5,000 (blue) for a sample of adults. a. Scattergram of incremental costs and DALYs averted for 80% MDA coverage b. Scattergram of incremental costs and unit increase in probability of elimination for 65% MDA coverage c. EVSI per person for the estimated optimum WTP per unit increase in elimination. Note: The comparator chosen as the reference template is <1% mf prevalence as the stopping threshold for TAS in children. The ellipses estimated from the covariance matrix and the mean vectors of each baseline prevalence (class labels) denote the 95% confidence intervals accounting for the uncertainty and variability within the distribution of each class. Each symbol represents the mean of the incremental costs to DALYs averted or probability of elimination classified by their respective baseline prevalences.

6b. we find the scattergram of the costs with DALYs averted₇₂₇ 706 in addition to the probability of elimination show when <0.5%₇₂₈ 707 stopping thresholds are cost-effective with a narrower estimated₇₂₉ 708 WTP_{Elimination} per unit increase in the probability of elimina-730 709 tion from \$500-\$3000 for 65% MDA coverage when predicted731 710 on the unseen 20% of the feature vector (test sample). Simi-732 711 larly, each symbol here represents the mean incremental costs733 712 to incremental probability for elimination to obtain a standard-734 713 ized comparison to the EINMB metric in Figure 4b. We re-735 714 mark that the results illustrated in Figure 6 a and b were com-715 puted using Step 1-3 of Algorithm 2 with 80% training sample 716 size. Finally, in Figure 6c, we illustrate the EVSI per person 717 using the utility gained from additional information predicted₇₃₇ 718 from LDA (see Algorithm 2 for more details) with the optimum₇₃₈ 719 WTP_{Elimination} estimated. We observe that as baseline preva-739 720 lence decreases, the optimum WTP_{Elimination} to make the lower₇₄₀ 721 stopping threshold cost-effective increases due to more addi-741 722 tional benefits gained from elimination and DALYs averted as742 723 demonstrated in Figure 3. Consequently, in Tables B.9 and B.10743 724 (refer to Supplementary Appendix B), we present the classifi-744 725 cation error for accurately predicting the baseline prevalences745 726

(class labels) for different stopping thresholds which decreases as training sample sizes increase. This improvement enhances the power of the utility function, which reflects the additive benefits gained with varying stopping thresholds, as indicated by the EVSI metric. This effect is achieved by training the LDA classifier with different fractions of the sample sizes, demonstrating that larger training datasets lead to more accurate classifications and thus greater potential benefits from additional data.

6. Discussion

The probability of local elimination is determined by stopping thresholds, which are crucial for many disease control policies. That being said, it would be worthwhile to look into the effects of a lower threshold on program costs overall as well as whether it raises the likelihood of local elimination. The application of such a lower threshold in China [57] and its significance in effective LF control serve as examples of the potential advantages of a lower threshold, which this study highlights. However, the GPELF can use this example to gather crucial

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

data in order to establish standards for assessing whether MDA⁸⁰³
 has been successful in bringing the infection prevalence down⁸⁰⁴
 to a point where recrudescence is unlikely to happen.

As we reduce the mf prevalence threshold from <1% to₈₀₆ 749 <0.5%, the likelihood of local elimination increases, accord-807 750 ing to our analysis of the effects of various stopping thresholds808 751 for TAS across 30 sites. Diminished DALY burden and restart809 752 probability are mitigated by a lower threshold, despite requir-810 753 ing more rounds. Employing the defined EINMB metric for811 754 CEA reveals that switching to a lower threshold is economical⁸¹² 755 at 80% MDA coverage. However, for 65% MDA coverage, ex-813 756 tra benefits are needed, such as utilizing the WTP_{Elimination} per₈₁₄ 757 unit increase for elimination. The low amount of data, espe-815 758 cially on systematic non-adherence and wider disease impacts816 759 like mental illness, is the reason for the conservative morbidity817 760 estimates [49; 30]. 761 818

The expanded use of CEA in healthcare faces several chal-819 762 lenges. First, decision-makers must account for social concerns820 763 like prioritizing the sick, reducing health disparities by inte-821 764 grating more social concerns into CEA techniques. Second,822 765 current CEA practices, focused on evaluating new strategies OT823 766 technologies, often overlook signs of resource misallocation.824 767 Third, assessing the broad range of interventions needed for₈₂₅ 768 CEA to improve allocative efficiency can be prohibitively ex-826 769 pensive and time-consuming. Additionally, many CEA studies827 770 produce context-specific results, limiting their applicability to828 771 different populations. Progress towards providing timely, af-829 772 fordable information on the costs and effects of various inter-830 773 ventions remains limited, particularly for LMIC [48; 60]. 774 831 On the other hand, the Linear Wasserstein Framework de-832 775 spite being mathematically rigorous has its own limitations.833 776 Firstly, the framework makes several modelling assumptions.834 777 Namely, that the distance should be proportional to the cost of₈₃₅ 778 translations. This can make the distance sensitive to outliers.836 779 Secondly, the Linear Wasserstein distance is also an approxi-780 mation of the Wasserstein distance and this approximation may 781 deteriorate depending on the local curvature. Thirdly, being837 782 balanced, this framework requires equal number of datapoints 783 (1000) for each probability measures derived from each of the838 784 pointcloud data for the different baseline prevalences (classes) 785 which can disproportionately affect the robustness of the re-786 sults, if class-imbalance exists. A further extension to this839 787 framework could be to generate future projections of the model 788 simulations for different baseline prevalences using fewer runs840 789 to save the computational power of the TRANSFIL model from841 790 a Bayesian perspective [37] or use state-of-art methods such as842 791 graph-based semi-supervised methods [9] that can leverage the843 792 advantages of this geometric embedding when very little infor-844 793 mation on the data is provided so that it can learn the geometry845 794 of the underlying point cloud data effectively. 846 795

Our study assumes constant survey implementation costs,⁸⁴⁷ excluding potential out-of-pocket expenses and future cost⁸⁴⁸ changes [41]. Despite challenges in estimating precise cost⁸⁴⁹ for MDA and TAS due to incomplete records and data access⁸⁵⁰ issues, simulations help understand the TAS threshold's im-⁸⁵¹ pact on stopping MDA. A limitation in this study is the exclu-⁸⁵² sion of vector control benefits, which remain debated. While⁸⁵³

some studies suggest combined MDA and vector control benefits in low endemic regions, others find no added advantage over MDA alone upon which further research is needed. Another major limitation is that our modelling study relies on Culex vector due to its increased efficiency in transmission. Although direct implication of Culex species in the transmission of LF in West and Central Africa is still not well documented [42; 4], in East Africa, Culex species particularly Cx. quinquefasciatus is known to have a major role in LF transmission [17; 33]. With changing climate associated to increased traffic between East and West African countries and rapid expansion of this species in urban settings, it is becoming crucial to assess the role of *Culex* species in the transmission of diseases like LF. We also restrict our analysis to the IA drug, but studies [50] for oncho have found that IA may not lead to elimination of transmission (EoT) in all endemic areas and moxidectin-based strategies could accelerate progress toward EoT and reduce programmatic delivery costs compared with ivermectin-based strategies. We also note that the use of the three-drug combination IDA, has particular challenges [45] for survey design due to reductions in mf density but not Ag over one or two rounds of treatment [27].

Despite these drawbacks, our research emphasizes how important it is to choose the right framework for uncertainty quantification when making decisions, especially when it comes to disease interventions, particularly LF. It is also essential to comprehend the dynamics of local elimination post-threshold crossing and how it interacts with LF interventions. Our research indicates that although there is a long transient phase involved in the path to LF local elimination post-MDA surveillance, lower thresholds may help programs achieve their objectives. In addition, we also propose the need for better framework to quantify the uncertainty inherent in the model parameters to analyze the cost-effectiveness of lowering the stopping threshold in LF.

7. Competing interests

The authors declare no competing interests.

8. Funding

MCAO, MG and TDH were supported by funding from the Bill & Melinda Gates Foundation (INV-030046), via the NTD Modelling Consortium. TDH is supported by funding from the Li Ka Shing Foundation at the Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford. MT would like to acknowledge the support of the Leverhulme Trust Research through the Project Award "Robust Learning: Uncertainty Quantification, Sensitivity and Stability" (grant agreement RPG-2024-051) and the EPSRC Mathematical and Foundations of Artificial Intelligence Probabilistic AI Hub (grant agreement EP/Y007174/1). LP gratefully acknowledges funding from the Wellcome Trust and Royal Society Sir Henry Dale Fellowship (202562/Z/16/Z), the Wellcome Trust Discovery Award "Harnessing epidemiological and

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

928

929

930

931

943

944

945 946

genomic data for understanding of respiratory virus transmis-914 854 sion at multiple scales" (227438/Z/23/Z) and the UKRI Im-915 855 pact Acceleration Award (IAA 386). KBP is supported by the⁹¹⁶ 856 Medical Research Foundation (MRF-160-0017-ELP-POUW-918 857 C0909). MCAO acknowledges the receipt of funding obtained 919 858 from the Health Data Research UK-The Alan Turing Insti-920 859 tute Wellcome (Grant Ref: 218529/Z/19/Z) and the Cambridge⁹²¹₉₂₂ 860 Trust scholarship from the Commonwealth European and In-923 861 ternational Trust (CCEIT). The funders had no role in study de-924 862 sign, data collection and analysis, decision to publish, or prepa-925 863 926 ration of the manuscript. 864 927

9. CRediT authorship contribution statement

Mary Chriselda Antony Oliver: Conceptualization, Method-932 ology, Software, Formal analysis, Writing-original draft, 867 Writing-review and editing, Visualization. Matthew Graham:935 868 Software, Writing- review and editing. Ioanna Manolopoulou,936 869 Graham F. Medley, Lorenzo Pellis - Writing- review and937 870 editing. Koen B Poewels, Matthew Thorpe, T. Deirdre₉₃₉ 871 Hollingsworth - Conceptualization, Methodology, Writing - re-940 872 view and editing, Supervision. 873 942

References

898

899

900

901

- Anderson, R.M. and May, R. (1992) Infectious Diseases of Humans: Dy-ga7 namics and Control of (Paper Backed) Oxford. Oxford University Press.
 New York.
- Antillon, Marina et al. "Economic evaluation of disease elimination:₉₅₀
 An extension to the net-benefit framework and application to human₉₅₁
 African trypanosomiasis." Proceedings of the National Academy of Sci-952
 ences of the United States of America vol. 118,50 (2021): e2026797118.
 doi:10.1073/pnas.2026797118.
- [3] Antony Oliver, Mary Chriselda et al. "Reducing the Antigen Prevalence₉₅₅
 Target Threshold for Stopping and Restarting Mass Drug Administration₉₅₆
 for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness₉₅₇
 Simulation in Tanzania, India and Haiti." Clinical infectious diseases :₉₅₈
 an official publication of the Infectious Diseases Society of America vol.₉₅₉
 78,Supplement 2 (2024): S160-S168. doi:10.1093/cid/ciae108
- [4] Appawu, M A et al. "Lymphatic filariasis in Ghana: entomological inves-⁹⁶¹ tigation of transmission dynamics and intensity in communities served₉₆₂ by irrigation systems in the Upper East Region of Ghana." Tropical₉₆₃ medicine & international health : TM & IH vol. 6,7 (2001): 511-6.⁹⁶⁴ doi:10.1046/j.1365-3156.2001.00737.x
- [5] Basu, Saurav et al. "Detecting and visualizing cell phenotype differences₉₆₆
 from microscopy images using transport-based morphometry." Proceed-₉₆₇
 ings of the National Academy of Sciences of the United States of America₉₆₈
 vol. 111,9 (2014): 3448-53. doi:10.1073/pnas.1319779111
 - [6] Bojke, Laura et al. "Characterizing structural uncertainty in decision₉₇₀ analytic models: a review and application of methods." Value in₉₇₁ health: the journal of the International Society for Pharmacoeconomics₉₇₂ and Outcomes Research vol. 12,5 (2009): 739-49. doi:10.1111/j.1524₉₇₃ 4733.2008.00502.x
- [7] Brady, Molly A et al. "Costs of Transmission Assessment Surveys₉₇₅
 to Provide Evidence for the Elimination of Lymphatic Filariasis."₉₇₆
 PLoS Neglected Tropical Diseases vol. 11,2 e0005097. 1 Feb. 2017₉₇₇
 doi:10.1371/journal.pntd.0005097.
- [8] Brennan, Alan et al. "Calculating partial expected value of perfect infor-⁹⁷⁹ mation via Monte Carlo sampling algorithms." Medical decision making₉₈₀
 an international journal of the Society for Medical Decision Making vol.₉₈₁
 27,4 (2007): 448-70. doi:10.1177/0272989X07302555
- [9] Calder, Jeff et al. "Poisson Learning: Graph Based Semi-Supervised₉₈₃
 Learning At Very Low Label Rates." International Conference on Ma-₉₈₄
 chine Learning (2020).

- [10] Caroline Moosmüller, Alexander Cloninger, Linear optimal transport embedding: provable Wasserstein classification for certain rigid transformations and perturbations, Information and Inference: A Journal of the IMA, Volume 12, Issue 1, March 2023, Pages 363–389, https://doi.org/10.1093/imaiai/iaac023
- [11] Cedric, Villani. Topics in Optimal Transportation. American Mathematical Society, 2003.
- [12] Chi, Y-Ling et al. "What next after GDP-based cost-effectiveness thresholds?." Gates open research vol. 4 176. 30 Nov. 2020, doi:10.12688/gatesopenres.13201.1
- [13] Chan, M S et al. "Epifil: a dynamic model of infection and disease in lymphatic filariasis." The American Journal of tropical medicine and Hygiene vol. 59,4 (1998): 606-14. doi:10.4269/ajtmh.1998.59.606.
- [14] Chu BK, Hooper PJ, Bradley MH, et al. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). PLoS Negl Trop Dis 2010;4:e708.
- [15] Claxton, K., et al. "Probabilistic Sensitivity Analysis for Decision Making in Health Care: The Value of Collecting Information." Medical Decision Making, 2005.
- [16] Davis, E. L., Reimer, L. J., Pellis, L., and Hollingsworth, T. D. (2019). Evaluating the Evidence for Lymphatic Filariasis Elimination. Trends in parasitology, 35(11), 860–869. https://doi.org/10.1016/j.pt.2019.08.003
- [17] Derua YA, Rumisha SF, Batengana BM, Max DA, Kisinza WN, Mboera LE. Lymphatic filariasis transmission on Mafia Islands, Tanzania: Evidence from xenomonitoring in mosquito vectors. PLoS neglected tropical diseases. 2017;11(10):e0005938 10.1371/journal.pntd.0005938
- [18] Dyson, Louise et al. "Measuring and modelling the effects of systematic non-adherence to mass drug administration." Epidemics vol. 18 (2017): 56-66. doi:10.1016/j.epidem.2017.02.002
- [19] Gambhir, Manoj, and Edwin Michael. "Complex ecological dynamics and eradicability of the vector borne macroparasitic disease, lymphatic filariasis." PloS one vol. 3,8 e2874. 6 Aug. 2008, doi:10.1371/journal.pone.0002874
- [20] Griffin, S., Fusco, F., Naidoo, B., Taylor, M., & Walker, S. M. (2020). Does Health Technology Assessment guidance give adequate consideration to decisions about less costly and less effective alternatives? (CHE Research Paper; No. 175). Centre for Health Economics, University of York.
- [21] Global Burden of Disease Study 2019 (GBD 2019) Disability Weights. http://ghdx.healthdata.org/record/ihme-data/gbd-2019-disabilityweights. Accessed 25 March 2022.
- [22] Heath A, Manolopoulou I, Baio G. Estimating the expected value of partial perfect information in health economic evaluations using integrated nested Laplace approximation. Stat Med. 2016;35(23):4264–80.
- [23] Heath, Anna et al. "Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression." Medical decision making : an international journal of the Society for Medical Decision Making vol. 39,4 (2019): 346-358. doi:10.1177/0272989X19837983.
- [24] Irvine, Michael A et al. "Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study." The Lancet. Infectious diseases vol. 17,4 (2017): 451-458. doi:10.1016/S1473-3099(16)30467-4
- [25] Irvine, Michael A et al. "Modelling strategies to break transmission of lymphatic filariasis–aggregation, adherence and vector competence greatly alter elimination." Parasites & vectors vol. 8 547. 22 Oct. 2015, doi:10.1186/s13071-015-1152-3.
- [26] Irvine, Michael A et al. "Understanding the relationship between prevalence of microfilariae and antigenaemia using a model of lymphatic filariasis infection." Transactions of the Royal Society of Tropical Medicine and Hygiene vol. 110,2 (2016): 118-24. doi:10.1093/trstmh/trv096.
- [27] James, Ananthu et al. "Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 78,Supplement 2 (2024): S131-S137. doi:10.1093/cid/ciae019
- [28] King, Christopher L et al. "A Trial of a Triple-Drug Treatment for Lymphatic Filariasis." The New England journal of medicine vol. 379,19 (2018): 1801-1810. doi:10.1056/NEJMoa1706854
- [29] Kunst, Natalia et al. "Computing the Expected Value of Sample Infor-

- mation Efficiently: Practical Guidance and Recommendations for Fourose
 Model-Based Methods." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 23,6058
 (2020): 734-742. doi:10.1016/j.jval.2020.02.010
- [30] Koschorke, Mirja et al. "Mental health, stigma, and neglected tropicalo60 diseases: A review and systematic mapping of the evidence." Frontiers ino61 Tropical Diseases (2022).
- 992[31]Kolouri, Soheil et al. "Optimal Mass Transport: Signal processing andos3
machine-learning applications." IEEE signal processing magazine volu66499434,4 (2017): 43-59. doi:10.1109/MSP.2017.2695801.1065
- [32] Kolouri, Soheil and Gustavo Kunde Rohde. "Transport-based single066
 frame super resolution of very low resolution face images." 2015 IEEE067
 Conference on Computer Vision and Pattern Recognition (CVPR) (2015)1068
 4876-4884. 1069
- [33] Mwakitalu, Mbutolwe E et al. "Urban lymphatic filariasis in the metropo+070 lis of Dar es Salaam, Tanzania." Parasites & vectors vol. 6 286. 30 Sept071 2013, doi:10.1186/1756-3305-6-286
- [34] Michael E, Singh BK. Heterogeneous dynamics, robustness/fragility073
 trade-offs, and the eradication of the macroparasitic disease, lymphatic074
 filariasis. BMC Med 2016; 14:14.
- 1005
 [35]
 Ochalek, Jessica et al. "Estimating health opportunity costs in low4076 income and middle-income countries: a novel approach and evidence077 from cross-country data." BMJ Global Health vol. 3,6 e000964. 5 Nov1078 2018, doi:10.1136/bmjgh-2018-000964.
- 1009
 [36]
 Ozolek, John A et al. "Accurate diagnosis of thyroid follicular lesionsom

 1010
 from nuclear morphology using supervised learning." Medical imageost

 1011
 analysis vol. 18,5 (2014): 772-80. doi:10.1016/j.media.2014.04.004
- [37] Park, S. & Thorpe, M. Representing and Learning High Dimensionalos3
 Data with the Optimal Transport Map from a Probabilistic Viewpoint1084
 In 2018 IEEE/CVF Conference on Computer Vision and Pattern Recog1085
 nition, 7864–7872, https://doi.org/10.1109/CVPR.2018.00820.
- [38] Pichon-Riviere, Andres et al. "Determining the efficiency path to univer+087 sal health coverage: cost-effectiveness thresholds for 174 countries based088 on growth in life expectancy and health expenditures." The Lancet. Global089 health vol. 11,6 (2023): e833-e842. doi:10.1016/S2214-109X(23)00162.1090
- [39] Rothery, Claire et al. "Value of Information Analytical Methods: Reportos1
 2 of the ISPOR Value of Information Analysis Emerging Good Practices092
 Task Force." Value in health : the journal of the International Society for093
 Pharmacoeconomics and Outcomes Research vol. 23,3 (2020): 277-2861094
 doi:10.1016/j.jval.2020.01.004.
- 1025[40]Stone CM, Kastner R, Steinmann P, et al, Modelling the health impact andose1026cost-effectiveness of lymphatic filariasis eradication under varying lev40971027els of mass drug administration scale-up and geographic coverage.BMJ0981028Global Health 2016;1:e000021
- 1029
 [41] Sawers, Larry, and Eileen Stillwaggon. "Economic Costs and Benefits of 100

 1030
 Community-Based Lymphedema-Management Programs for Lymphatic101

 1031
 Filariasis in India." The American journal of tropical medicine and hy+102

 1032
 giene vol. 103,1 (2020): 295-302. doi:10.4269/ajtmh.19-0898.

 1033
 1103
- [42] Samy AM, Elaagip AH, Kenawy MA, Ayres CF, Peterson AT, Soli man DE. Climate change influences on the global potential distribution
 of the mosquito Culex quinquefasciatus, vector of West Nile virus and
 lymphatic filariasis. PLoS ONE. 2016;11(10):e0163863 10.1371/jour nal.pone.0163863
- [43] Strong M, Oakley J, Brennan A, Breeze P. Estimating the expected value
 of sample information using the probabilistic sensitivity analysis sample a fast nonparametric regression-based method. Med Decis Making.
 2015;35(5): 570–83.
- [44] Strong M, Oakley JE. When is a model good enough? Deriving the expected value of model improvement via specifying internal model discrepancies.SIAM/ASA Journal on Uncertainty Quantification.
 2014;2(1):106–125.
- [45] Stolk WA, Prada JM, Smith ME, et al. Are alternative strategies required
 to accelerate the global elimination of lymphatic filariasis? Insights from
 mathematical models. Clin Infect Dis 2018; 66:2606.
- 1049[46]Stolk, Wilma A et al. "Comparing antigenaemia- and microfilaraemia1050as criteria for stopping decisions in lymphatic filariasis elimination1051programmes in Africa." PLoS Neglected Tropical Diseases vol. 16,121052e0010953. 12 Dec. 2022, doi:10.1371/journal.pntd.0010953
- [47] Stolk, Wilma A et al. "Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis." PLoS Neglected Tropical Diseases vol. 7,1 (2013): e1984.

doi:10.1371/journal. and.0001984.

- [48] Turner, Hugo C et al. "An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations." Frontiers in public health vol. 9 722927. 25 Aug. 2021, doi:10.3389/fpubh.2021.722927
- [49] Ton, T.G., Mackenzie, C. and Molyneux, D.H. The burden of mental health in lymphatic filariasis. Infect Dis Poverty 4, 34 (2015). https://doi.org/10.1186/s40249-015-0068-7
- [50] Turner, Hugo C et al. "An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 78,Supplement 2 (2024): S138-S145. doi:10.1093/cid/ciae054.
- [51] Turner, Hugo C et al. "Adjusting for Inflation and Currency Changes Within Health Economic Studies." Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 22,9 (2019): 1026-1032. doi:10.1016/j.jval.2019.03.021
- [52] Vallejo-Torres, Laura et al. "Challenges of calculating cost-effectiveness thresholds." The Lancet. Global health vol. 11,10 (2023): e1508. doi:10.1016/S2214-109X(23)00351-0
- [53] World Health Organization (WHO). Weekly Epidemiological Record (WER), 13 October 2023, Vol. 98, No. 41, pp. 489 - 502.
- [54] World Health Organization (WHO). Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration, a manual for national elimination programmes. Geneva, Switzerland: WHO, 2011, page 29.
- [55] W. Wang, D. Slepcev, S. Basu, J. A. Ozolek, and G. K. Rohde, "A linear optimal transportation framework for quantifying and visualizing variations in sets of images," Int. J. Comput. Vision, vol. 101, no. 2, pp. 254–269, 2013.
- [56] Wilson E. A Practical Guide to Value of Information Analysis. PharmacoEconomics 2015; 33(2):105–121.
- [57] World Health Organization Regional Office for the Western Pacific, Control of Lymphatic Filariasis in China Editorial Board. Control of lymphatic filariasis in China. Manila: World Health Organization Regional Office for the Western Pacific; 2003.
- [58] Wang, W., Mo, Y., Ozolek, J.A., Rohde, G.K.: Penalized discriminant analysis and its application to image-based morphometry. Pattern Recognition Letters.
- [59] Willis, Gabriela A et al. "A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018." PLoS neglected tropical diseases vol. 14,11 e0008854. 30 Nov. 2020, doi:10.1371/journal.pntd.0008854.
- [60] World Health Organization, Baltussen, Rob M. P. M, Adam, Taghreed, Tan-Torres Edejer, Tessa, Hutubessy, Raymond C. W. et al. (2003). Making choices in health : WHO guide to cost-effectiveness analysis. World Health Organization.